Biocartis’ Idylla™ SARS-CoV-2 testing successfully detects Omicron variant
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the Company performed an in-silico analysis which concluded that the Idylla™ SARS-CoV-2 Test (CE-IVD) and the Idylla™ SARS-CoV-2/Flu/RSV (1) Panel (CE-IVD) detect the currently available B.1.1.529/Omicron sequences, the new variant of concern causing COVID-19 disease.
The Idylla™ SARS-CoV-2 Test and Idylla™ SARS-CoV-2/Flu/RSV Panel have a dual target technology built in the assay, which increases resilience against mutations like those found in Omicron.
The Idylla™ SARS-CoV-2 Test is an automated rRT-PCR (2) test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens from individuals suspected of COVID-19 by their healthcare provider. The Idylla™ SARS-CoV-2/Flu/RSV Panel is a fully automated rRT-PCR test intended for the detection of SARS-CoV-2, Flu A, Flu B and RSV nucleic acids in nasopharyngeal swab specimens from individuals suspected of respiratory infections by their healthcare provider. Both tests have results available in 90 minutes with less than 2 minutes hands-on time (3).
Biocartis is performing regular in-silico analysis for current and emerging strains. More info on the Idylla™ SARS-CoV-2 testing solutions can be found on the Biocartis website here.
(1) Respiratory Syncytial Virus
(2) Real-Time Reverse Transcription-Polymerase Chain Reaction
(3) For the Idylla™ SARS-CoV-2 Test, results are obtained using 200 μl of viral transport media (VTM). For the Idylla™ SARS-CoV-2/Flu/RSV Panel, results are obtained using 400 μl of viral transport media (VTM) pipetted directly into the cartridge. Both tests are performed on the Idylla™ platform capable of fully automated nucleic acid testing including extraction, amplification, and detection in a single-use cartridge. For additional performance characteristics, please refer to the Instructions for Use or the Biocartis website here and here